Guerra F, Rodríguez J G, Brümmer E, Campos G, do al Luz Muñoz M
Instituto de Obstetricia y Ginecologia, Facultad de Medicina, Universidad Austral de Chile, Valdivia.
Rev Chil Obstet Ginecol. 1994;59(3):185-9.
Sulindac and indometacin, both prostaglandins inhibitors, have a similar tocolytic effectiveness, in contrast their fetal effects seem to be different. For specify these differences we compared the effects of the infusion of sulindac with known effects of indometacin. We operated 6 fetal lambs, in which polyvinyl catheters were inserted chronically for continuous measure of heart rate, blood pressure, incidence of fetal breathing movements and arterial pH and gas tension. The fetuses were infused in a 2 hour control period with vehicle, and then with 150 mg of either sulindac or indometacin (in alternate days) for a 6 hour period. There was no change in any variable when sulindac was given, but there was a significant increase in fetal breathing movements with indometacin. The reason for this difference is not clear, and requires further studies. These results added to previous reports supports the hypothesis that sulindac could be a first choice tocolytic drug for treatment of premature labor when no fetal effect is desired.
舒林酸和吲哚美辛都是前列腺素抑制剂，二者具有相似的抑制宫缩效力，然而它们对胎儿的影响似乎有所不同。为明确这些差异，我们将舒林酸输注的效果与吲哚美辛已知的效果进行了比较。我们对6只胎羊进行了手术，长期插入聚乙烯导管以持续测量心率、血压、胎儿呼吸运动发生率以及动脉pH值和血气张力。在2小时的对照期内，给胎儿输注赋形剂，然后在接下来的6小时内交替给予150毫克舒林酸或吲哚美辛。给予舒林酸时，任何变量均无变化，但给予吲哚美辛时胎儿呼吸运动显著增加。这种差异的原因尚不清楚，需要进一步研究。这些结果与先前的报道共同支持了这样一种假说，即当不希望对胎儿产生影响时，舒林酸可能是治疗早产的首选宫缩抑制剂。
